Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Dr. Reddy's Laboratories Ltd Common Stock (NY:RDY)

14.10 -0.21 (-1.47%)
Streaming Delayed Price Updated: 11:23 AM EST, Feb 13, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Dr. Reddy's Laboratories Ltd Common Stock

< Previous 1 2 3 4 5 6 7 8 Next >
News headline image
Dr. Reddy's Laboratories Announces the Launch of Regadenoson Injection 0.4 mg/5 mL in the U.S.
From Dr. Reddy's Laboratories Ltd.
Via Business Wire
News headline image
Dr. Reddy's Laboratories Announces the Launch of Treprostinil Injection in the U.S.
From Dr. Reddy's Laboratories Ltd.
Via Business Wire
News headline image
Why Aditxt Shares Are Surging Today ↗
Aditxt, Inc. (NASDAQ: ADTX) stock is surging Thursday as it expands its portfolio to include innovative therapies for infectious diseases. 
Via Benzinga
News headline image
Intercept Settles Ocaliva Litigation With Reddy's Lab ↗
 
Via Benzinga
News headline image
India Based Pharma Companies In Race To Buy Athenex, Shares Surge ↗
 
Via Benzinga
Dr. Reddy’s Laboratories Ltd. (NYSE: RDY) Making Surprising Moves in Wednesday Session
Via Investor Brand Network
Dr. Reddy’s Laboratories Ltd. (NYSE: RDY) Sets New 52-Week High in Monday Session
Via Investor Brand Network
Coya Therapeutics Enters First-Of-Its-Kind Partnership With Multi-Billion Dollar Drug Company — Why This Is a Major Moment For Drug Development
By David Willey, Benzinga 
Via TheNewswire.com
News headline image
Coya Therapeutics Enters First-Of-Its-Kind Partnership With Multi-Billion Dollar Drug Company — Why This Is a Major Moment For Drug Development
Coya Therapeutics Enters First-Of-Its-Kind Partnership With Multi-Billion Dollar Drug Company — Why This Is a Major Moment For Drug Development 
Via News Direct
News headline image
Coya Therapeutics Enters First-Of-Its-Kind Partnership With Multi-Billion Dollar Drug Company — Why This Is A Major Moment For Drug Development ↗
Houston-based Coya Therapeutics (NASDAQ: COYA) has entered into a partnership with Dr. Reddy’s Laboratories Ltd. (NYSE: RDY), a world-leading pharmaceutical company based in India. 
Via Benzinga
News headline image
Houston-Based Coya Therapeutics Partners With Multi-Billion Dollar Global Drug Company Dr. Reddy’s Laboratories To License and Commercialize COYA 302
Houston-Based Coya Therapeutics Partners With Multi-Billion Dollar Global Drug Company Dr. Reddy’s Laboratories To License and Commercialize COYA 302 
Via News Direct
Houston-Based Coya Therapeutics Partners With Multi-Billion Dollar Global Drug Company Dr. Reddy’s Laboratories To License and Commercialize COYA 302
By Kenneth Adams, Benzinga 
Via TheNewswire.com
News headline image
Houston-Based Coya Therapeutics Partners With Multi-Billion Dollar Global Drug Company Dr. Reddy's Laboratories To License And Commercialize COYA 302 ↗
Coya Therapeutics, Inc. (NASDAQ: COYA) recently announced a worldwide agreement with Dr. Reddy’s Laboratories Limited. 
Via Benzinga
News headline image
Coya Therapeutics, Inc. Announces an Agreement with Dr. Reddy’s Laboratories, Ltd. to License its proposed biosimilar Abatacept for the Development and Commercialization of COYA 302 for the Treatment of Neurodegenerative Diseases
From Coya Therapeutics, Inc.
Via Business Wire
News headline image
Dr. Reddy's Seeks Gaining Foothold In Women's Health Via Mayne Pharma's U.S. Generic Prescription Deal ↗
 
Via Benzinga
News headline image
Dr. Reddy's Laboratories Announces Agreement to Acquire Mayne Pharma’s U.S. Generic Prescription Product Portfolio
From Dr. Reddy’s Laboratories Ltd.
Via Business Wire
News headline image
Dr. Reddy’s included in Bloomberg Gender-Equality Index for the 6th year in a row and S&P Global’s Sustainability Yearbook for the 3rd year
From Dr. Reddy’s Laboratories Ltd.
Via Business Wire
News headline image
The 3 Most Undervalued Stocks in India for Your February Buy List ↗
These are a few of the top undervalued stocks in India, providing investors with exposure to strong growth outlooks in the coming years. 
Via InvestorPlace
News headline image
Dr. Reddy's Laboratories announces the launch of Difluprednate Ophthalmic Emulsion 0.05% in the U.S. Market
From Dr. Reddy’s Laboratories Ltd.
Via Business Wire
News headline image
Intercept Surges To Four-Month High After Staving Off Amneal's Generic For 11 Years ↗
Intercept entered a deal with Amneal, likely lining up a series of new settlements. 
Via Investor's Business Daily
News headline image
Dr. Reddy’s successfully completes full set of clinical studies of its rituximab biosimilar for filing in the U.S., Europe
From Dr. Reddy’s Laboratories Ltd.
Via Business Wire
News headline image
Journey Medical Touts Positive PK Data For Bacterial Infection Candidate ↗
 
Via Benzinga
News headline image
Dr. Reddy’s Successfully Completes Phase 1 Study of DRL_TC, a Proposed Biosimilar of Tocilizumab
From Dr. Reddy’s Laboratories Ltd.
Via Business Wire
News headline image
Novartis Fails To Prevent Generic Competition For Its Blockbuster Multiple Sclerosis Drug ↗
The U.S. Supreme Court rejected Novartis AG's (NYSE: NVS) effort to block the launch of generic versions of its multiple sclerosis drug Gilenya. 
Via Benzinga
News headline image
World Economic Forum Recognises Dr. Reddy’s Hyderabad Factory as Part of its Global Lighthouse Network
From Dr. Reddy’s Laboratories Ltd.
Via Business Wire
News headline image
Dr. Reddy's Laboratories Announces the Launch of Lenalidomide Capsules in the U.S. With Two of Six Strengths Eligible for First-to-market, 180-day Exclusivity
From Dr. Reddy’s Laboratories Ltd.
Via Business Wire
News headline image
Is Sanofi A Buy, Despite Recent Stumbles?
Pharmaceuticals are subject to whiplash trade. That's evident with sharp moves lower in Sanofi, GSK and Teva on news about clinical trials and legal actions. 
Via MarketBeat
Topics Intellectual Property
News headline image
Biotech Daily: Thumbs Down For Acadia's Antipsychotic Drug, Akebia Fails COVID-19 Study, Kazia's Encouraging Data In Brain Metastases ↗
Here's a roundup of top developments in the biotech space over the last 24 hours: 
Via Benzinga
News headline image
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Friday ↗
Good morning! We're starting off the last day of trading this week with a breakdown of the biggest pre-market stock movers for Friday! 
Via InvestorPlace
News headline image
Dr. Reddy's Laboratories enters into a licensing agreement with Slayback Pharma to obtain exclusive rights in the first-to-file ANDA for the private label version of Lumify® in the U.S.
From Dr. Reddy’s Laboratories Ltd.
Via Business Wire
< Previous 1 2 3 4 5 6 7 8 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.